Company intelligence / Profile preview
Perceive Biotherapeutics
South San Francisco, California, USAperceivebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program VOY-101 is in Phase 1/2 for wet age-related macular degeneration. Other programs for dry AMD, glaucoma, and hearing disorders are in preclinical or discovery stages.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Gene therapySmall moleculesBiological products
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Perceive Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perceive Biotherapeutics.